Pharsight — Q1 FY2007 Earnings Presentation
37 slides from Pharsight's earnings presentation, Aug 3, 2006

Slide 1: Pharsight Corporation Investor Presentation
Exhibit 99.1 Pharsight Corporation Investor Presentation 1st Quarter Fiscal 2007 Update Shawn O’Connor President, Chairman and CEO Will Frederick CFO Confidential © Pharsight Corporation

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements, including statements regarding our financial model, growth opportunities and strategic investments, our market position, the demand and market opportunity for our products and services, financial and product performanc

Slide 3: Overview
Overview • Profile – Founded in 1995 with IPO in August 2000 – Offices in Mountain View, CA (HQ) and Cary, NC (R&D) – Global headcount approximately 90 – Stock traded OTCBB: PHST • Key Industry Considerations – Large Pharmaceutical and bio-tech marketplace – Outsourcing of development activities esc

Slide 4: Pharsight Enables Strategic Decision Making in Clinical Drug Development
Pharsight Enables Strategic Decision Making in Clinical Drug Development • Market-leading software improves the value and availability of clinical pharmacology data for PK/PD modeling, analysis and reporting, PK data repositories, and clinical trial simulation – Decisions are faster, more reliable a

Slide 5: Management Team
Management Team Shawn M. O’Connor President, Chairman and Chief Executive Officer QRS, Diasonics Ultrasound, Peat Marwick Will Frederick Chief Financial Officer Versata, Clarent, ACT Networks, Disney James Hayden SVP Global Sales Accelrys, Bio-Rad Laboratories, Raytheon Mark Hovde SVP Marketing Hovd

Slide 6: Market Opportunity: Drug Development Cost and Timeline
Market Opportunity Drug Development Cost and Timeline Research Clinical Development $25 Billion 1 $48 Billion 1 • High throughput screening • Long, risky and complex process • Combinatorial chemistry • Of 5,000 screened • Genomics compounds: 250 enter preclinical testing, 5 • Rational drug design en

Slide 7: Market Opportunity: Contract Research and Software
Market Opportunity Contract Research and Software Pharsight provides PK/PD consultancy and software primarily in Phases I, II-III, and IIIb-IV of the growing market for outsourced research services $25 $20 Other $15 Labs Phase IIIb-IV Phase II-III $10 Phase I Preclinical $5 Market CAGR = 14% $0 2005

Slide 8: FDA Influence: Critical Path Initiative
FDA Influence Critical Path Initiative FDA Issues Critical Path Paper - June 2004 • The Critical Path Initiative is FDA's effort to stimulate and facilitate a national effort to modernize the scientific process through which a potential human drug, biological product, or medical device is transforme

Slide 9: Return on Investment Example: sanofi-aventis
Return on Investment Example sanofi-aventis Aventis turned to a computer model from … Pharsight. Using its own animal and human test data, Aventis was able to simulate later-stage clinical trials. Based on that simulation, “we stopped funding development of the compound. The ratio between the therap

Slide 10: Return on Investment Example: Pfizer
Return on Investment Example Pfizer “Within 2 years of (implementing Pharsight’s WinNonlin automation and other measures) the two people conducting the routine pharmacokinetic studies had completed 45 studies in 1 year.” (previous staff of 19 for the same work) “The cycle time to issue final reports

Slide 11: Software Products
Software Products Confidential © Pharsight Corporation

Slide 12: Overview of Key Software Offerings
Overview of Key Software Offerings • Desktop Software Products – WinNonlin ® • Industry Standard for Pharmacokinetic (“PK”), Pharmacodynamic (“PD”) Modeling and Non Compartmental Analysis – WinNonMix ® • Population Pharmacokinetic Modeling and Simulation – Trial Simulator™ • Computer Assisted Clinic

Slide 13: Key Software Offerings: WinNonlin
Key Software Offerings WinNonlin ® (“WNL™”) Industry Standard for Pharmacokinetic (“PK”), Pharmacodynamic (“PD”) Modeling, and Non Compartmental Analysis • Key Benefits – Used to simulate effects of different dosing regimens and changes in pharmacokinetic parameters required in regulatory submission

Slide 14: Key Software Offerings: WinNonMix
Key Software Offerings WinNonMix ® (“WNM™”) Nonlinear Mixed Effects (Population) Analysis Software Application • Key Benefits – Extensive built-in library of PK, PD and PK-PD models – NONMEM data import wizard – Built-in report-ready graphics capability – Estimation algorithms for sparse and for ric

Slide 15: Key Software Offerings: Trial Simulator 2.0
Key Software Offerings Trial Simulator™ 2.0 (“TS2™”) State-of-the-Art Clinical Trial Design and Simulation Software • Key Benefits – Minimize risk of trial design – Formalize assumptions – Quantify uncertainty – Reduce cost of clinical trials and drug development time-to-market • Potential Growth Dr

Slide 16: Key Software Offerings: Pharsight Knowledgebase Server
Key Software Offerings Pharsight ® Knowledgebase Server™ (“PKS™”) Enterprise Data Management Systems for Secure Storage and Management of PK/PD Data • Key Benefits – Dramatically improves data management and data access – Increases productivity in analysis and reporting tasks – Supports compliance w

Slide 17: Key Software Offerings: Drug Model Explorer
Key Software Offerings Drug Model Explorer™ (“DMX ® ”) Software-Based Communication Technology, Designed to Facilitate Quantitative Decision-Making in Drug Development • Key Benefits – Facilitates more efficient collaboration within project teams to explore key drug attributes, and their respective

Slide 18: Software Products Market Acceptance
Software Products Market Acceptance 1 • Over 1,200 active software customers 2 • All Top 50 Pharma license at least one of our software products • Our software applications are licensed for use on more than 6,000 desktops in industry and academia 2 TM • 11 of the Top 50 Pharma are PKS customers TM –

Slide 19: Strategic Consulting Services
Strategic Consulting Services Confidential © Pharsight Corporation

Slide 20: Formal, quantitative, model-based decision-making method
Strategic Consulting Services Formal, quantitative, model-based decision-making method Increases drug development productivity Decreases late stage attrition Decreases time-to-market Reduces financial investment Improves clinical quality and commercial performance of final product Copyright © 2006 P

Slide 21: Quantitative Modeling Supports Both Trial- and Program-Level Decisions
Quantitative Modeling Supports Both Trial- and Program-Level Decisions Animal Human Treatment, Trial Market Patient Endpoints PK Data PK Data Exposure Outcomes Acceptance Drug and Patient Models Trial Models Market Models • Optimize treatment • Match trial design to • Choose the decision regimens an

Slide 22: Overview of Consulting Services
Overview of Consulting Services • World-class experts in clinical pharmacology, PK/PD, decision analysis, and statistics • Senior scientific leadership with extensive drug development experience • Seasoned practitioners from industry, academia, and consulting • Serving all major drug development geo

Slide 23: Strategic Consulting Services Potential Growth Drivers
Strategic Consulting Services Potential Growth Drivers • Industry Factors – Increased acceptance of modeling and simulation to achieve efficient drug development decision making – FDA Critical Path Initiative advocates increased use of modeling and simulation to overcome poor development productivit

Slide 24: Strategic Consulting Services Market Acceptance
Strategic Consulting Services Market Acceptance 1 • Over 35 active consulting clients YTD Fiscal Year 2007 – 20 of the Top 50 Pharma² are active consulting clients – 4 new consulting clients • Over 100 projects engaged during Fiscal Year 2006 – 24 new consulting clients • Diverse Customer Workplans

Slide 25: Financial Overview
Financial Overview Confidential © Pharsight Corporation

Slide 26: Accomplishments and Guidance
Accomplishments and Guidance FY06 Accomplishments FY07 Guidance • Revenue growth • Continued revenue growth – Y/Y revenue growth of 1% – Y/Y revenue growth of approx. 10% to – 3rd consecutive year of revenue growth 15% – 40% - 45% of revenue expected in 1H of year • Gross Margin • Gross Margin – 66%

Slide 27: Summary Income Statements
Summary Income Statements (in thousands) Q1 FY07 Q1 FY06 Consol. SPBU SCS Consol. SPBU SCS Revenue 5,428 3,046 2,382 5,694 2,490 3,204 Y/Y growth -5% 22% -26% 13% -6% 34% Cost of revenue 1,756 243 1,513 1,887 395 1,492 Gross profit 3,672 2,803 869 3,807 2,095 1,712 Gross margin 68% 92% 36% 67% 84% 5

Slide 28: Summary Balance Sheets
Summary Balance Sheets (in thousands) June 30, March 31, 2006 2006 ASSETS Cash & cash equivalents $ 10,170 $ 10,832 Accounts receivable, net 3,394 4,585 Total current assets 13,992 15,715 Total assets $ 15,921 $ 17,786 LIABILITIES & STOCKHOLDERS' DEFICIT A/P & accrued expenses $ 2,697 $ 3,981 Deferr

Slide 29: Annual Revenue by Business Unit
Annual Revenue by Business Unit (in thousands) $25,000 $20,000 $15,000 $10,000 $5,000 $0 FY03 FY04 FY05 FY06 Software Products Strategic Consulting Copyright © 2006 Pharsight Corporation. All rights reserved. 29

Slide 30: Quarterly Revenue by Business Unit
Quarterly Revenue by Business Unit (in thousands) $6,000 $5,000 $4,000 $3,000 $2,000 $1,000 $0 Q1 FY06 Q2 FY06 Q3 FY06 Q4 FY06 Q1 FY07 Software Products Strategic Consulting Copyright © 2006 Pharsight Corporation. All rights reserved. 30

Slide 31: Annual Gross Profit
Annual Gross Profit (in thousands) $17,500 $15,000 $12,500 $10,000 $7,500 $5,000 $2,500 $0 FY02 FY03 FY04 FY05 FY06 Copyright © 2006 Pharsight Corporation. All rights reserved. 31

Slide 32: Annual Operating Income
Annual Operating Income (in thousands) $5,000 $2,500 $0 -$2,500 -$5,000 -$7,500 -$10,000 -$12,500 -$15,000 -$17,500 -$20,000 FY02 FY03 FY04 FY05 FY06 Copyright © 2006 Pharsight Corporation. All rights reserved. 32

Slide 33: Annual Operating Cash Flow
Annual Operating Cash Flow (in thousands) $4,000 $2,000 $0 -$2,000 -$4,000 -$6,000 -$8,000 FY02 FY03 FY04 FY05 FY06 Copyright © 2006 Pharsight Corporation. All rights reserved. 33

Slide 34: Equity Overview
Equity Overview • Common Shares Outstanding¹ 19.7M • Preferred Shares Outstanding¹ 1.9M – 1.8 million Series A and 0.1 million Series B – Conversion ratio to Common at 4:1 • Common Equivalent Shares (as converted) ¹ 27.4M • PIPE Financing 6/02 and 9/02 = $7.5M – 1.8 million Units = 1 share Series A

Slide 35: Summary
Summary • Current pharmaceutical market trends look favorable… • Increasing mindshare for quantitative-based modeling and simulation… • FDA's call for more modeling and simulation in the Critical Path Initiative… • Financially stable and healthy business model… All support our drive towards expandin

Slide 36: Proprietary Notice
Proprietary Notice All contents Copyright ©2006 Pharsight Corporation. All rights reserved. The copyright for this document is owned by Pharsight Corporation. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, for

Slide 37: Pharsight
Pharsight Pharsight
Source: SEC EDGAR · 8-K filed Aug 3, 2006
More decks from Pharsight Corp
Q4 2007 Earnings Presentation45 slides · May 14, 2007
Investor Presentation (January 2007)41 slides · Jan 26, 2007
Q2 2007 Earnings Presentation33 slides · Nov 30, 2006
Investor Presentation (June 2006)36 slides · Jun 6, 2006
Investor Presentation (February 2006)31 slides · Feb 2, 2006
Investor Presentation (August 2005)39 slides · Aug 2, 2005